Literature DB >> 20547955

Economic cost of visual impairment in Japan.

Chris B Roberts1, Yoshimune Hiratsuka, Masakazu Yamada, M Lynne Pezzullo, Katie Yates, Shigeru Takano, Kensaku Miyake, Hugh R Taylor.   

Abstract

OBJECTIVE: To quantify the total economic cost of visual impairment in Japan.
METHODS: A prevalence-based approach was adopted using data on visual impairment, the national health system, and indirect costs to capture the economic impact of visual impairment in 2007.
RESULTS: In 2007, visual impairment affected more than 1.64 million people in Japan and cost around yen 8785.4 billion (US $72.8 billion) across the economy, equivalent to 1.7% of Japan's gross domestic product. The loss of well-being (years of life lost from disability and premature mortality) cost yen 5863.6 billion (US $48.6 billion). Direct health system costs were yen 1338.2 billion (US $11.1 billion). Other financial costs were yen 1583.5 billion (US $13.1 billion), including productivity losses, care takers' costs, and efficiency losses from welfare payments and taxes. Community care was the largest component of other financial costs and was composed of paid and unpaid services that provide home and personal care to people with visual impairment. The findings of this study are in line with those of similar studies in Australia and the United States.
CONCLUSIONS: Visual impairment imposes substantial costs on society, particularly to individuals with visual impairment and their families. Eliminating or reducing disabilities from visual impairment through public awareness of preventive care, early diagnosis, more intensive disease treatment, and new medical technologies could significantly improve the quality of life for people with visual impairment and their families, while also potentially reducing national health care expenditure and increasing productivity in Japan. The results of this study should provide a first step in helping policymakers evaluate policy effects and to prioritize research expenditures.

Entities:  

Mesh:

Year:  2010        PMID: 20547955     DOI: 10.1001/archophthalmol.2010.86

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  24 in total

1.  Association between SCO2 mutation and extreme myopia in Japanese patients.

Authors:  Tomotaka Wakazono; Masahiro Miyake; Kenji Yamashiro; Munemitsu Yoshikawa; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2016-04-06       Impact factor: 2.447

2.  Epidemiology, treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study.

Authors:  Ming-Chin Yang; Yen-Po Chen; Elise Chia-Hui Tan; Claudia Leteneux; Erin Chang; Carol Hy Chu; Chi-Chun Lai
Journal:  Jpn J Ophthalmol       Date:  2017-01-06       Impact factor: 2.447

3.  Reconsideration of the most appropriate criterion in the lowest classification of vision disability in Japan.

Authors:  Tomomi Nishida; Noburo Ando; Kazushige Sado; Satoshi Nakadomari
Journal:  Jpn J Ophthalmol       Date:  2011-08-24       Impact factor: 2.447

4.  Vision-related quality of life in Japanese patients with wet age-related macular degeneration treated with intravitreal aflibercept in a real-world setting.

Authors:  Fumi Gomi; Hideyuki Migita; Toshiaki Sakaguchi; Hiromi Okada; Tamotsu Sugawara; Yusuke Hikichi
Journal:  Jpn J Ophthalmol       Date:  2019-10-31       Impact factor: 2.447

5.  Prevalence of nonrefractive visual impairment in US adults and associated risk factors, 1999-2002 and 2005-2008.

Authors:  Fang Ko; Susan Vitale; Chiu-Fang Chou; Mary Frances Cotch; Jinan Saaddine; David S Friedman
Journal:  JAMA       Date:  2012-12-12       Impact factor: 56.272

6.  Changes in dry eye diagnostic status following implementation of revised Japanese dry eye diagnostic criteria.

Authors:  Yuichi Uchino; Miki Uchino; Murat Dogru; Samantha Ward; Norihiko Yokoi; Kazuo Tsubota
Journal:  Jpn J Ophthalmol       Date:  2011-11-15       Impact factor: 2.447

7.  Clinical practice of diabetic foot, nephropathy, and retinopathy in Japan: cross-sectional study using local and nationwide questionnaire surveys.

Authors:  Yukihiro Fujita; Masakazu Haneda
Journal:  Diabetol Int       Date:  2021-11-26

8.  Assessing quality of life in the treatment of patients with age-related macular degeneration: clinical research findings and recommendations for clinical practice.

Authors:  Mitsuko Yuzawa; Kyoko Fujita; Erika Tanaka; Edward C Y Wang
Journal:  Clin Ophthalmol       Date:  2013-07-01

Review 9.  What the comprehensive economics of blindness and visual impairment can help us understand.

Authors:  Kevin D Frick
Journal:  Indian J Ophthalmol       Date:  2012 Sep-Oct       Impact factor: 1.848

10.  The Prevalence and Causes of Visaual Impairment and Blindness in a Rural Population in the North of Iran.

Authors:  Hassan Hashemi; Farhad Rezvan; AbbasAli Yekta; Hadi Ostadimoghaddam; Sara Soroush; Nooshin Dadbin; Mehdi Khabazkhoob
Journal:  Iran J Public Health       Date:  2015-06       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.